In vitro activity of anidulafungin against selected clinically important mold isolates
about
Melanized fungi in human diseaseSporothrix schenckii and SporotrichosisHospital-acquired phaeohyphomycosis due to Exserohilum rostratum in a child with leukemiaInfections caused by Scedosporium spp.Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist*Use of amplified fragment length polymorphism to identify 42 Cladophialophora strains related to cerebral phaeohyphomycosis with in vitro antifungal susceptibility.Penicillium marneffei Infection in AIDS.Antifungal susceptibility patterns of opportunistic fungi in the genera Verruconis and Ochroconis.Mycetoma medical therapy.Anidulafungin: an echinocandin antifungal.In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methodsRare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.Echinocandin antifungals: review and update.The safety of anidulafungin.The echinocandins.Anidulafungin--state of affairs from a clinical perspective.Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007).Anidulafungin: a novel echinocandin for candida infections.Anidulafungin: an evidence-based review of its use in invasive fungal infections.Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections?Echinocandins in antifungal pharmacotherapy.In Vitro Activity of Posaconazole against Talaromyces marneffei by Broth Microdilution and Etest Methods and Comparison to Itraconazole, Voriconazole, and Anidulafungin.[Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer].Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents.Lipid formation and γ-linolenic acid production by Mucor circinelloides and Rhizopus sp., grown on vegetable oil.Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008).Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1,3 glucan levels in culture.Anidulafungin and its role in candida infectionsWhite grain mycetoma caused by Scedosporium apiospermum in North India: a case report.In vitro activities of antifungal drugs against Rhinocladiella mackenziei, an agent of fatal brain infection.Microdilution in vitro antifungal susceptibility of Exophiala dermatitidis, a systemic opportunist
P2860
Q24633163-EF27CF70-7EF9-409D-A798-C46E11682B1BQ24635012-30A11D90-A595-4251-BDE8-75F858A9FB27Q24652237-704110F1-12D2-4689-83BD-936D6041596EQ24657691-408C55C7-4AC0-4F69-82AD-0610FE232C08Q28315344-1EAE1D99-B3E2-4419-AEFF-1E6E3D8FC5C4Q33565219-B5288AB3-F168-4A9E-8AA4-BF177E488A13Q34572362-7B683775-1AF4-4AD3-868F-C5ADD7E295F7Q35136368-805BF200-B684-4B75-8B7E-859A2079C37DQ35351362-E71C4EA4-471C-4698-B894-A9AA457116C1Q35871936-757751F2-CDF5-43EE-8A4B-337479EC3C9FQ35879091-A1240B80-1BBB-43EE-A4B4-0D98709221E0Q35912243-6F1BE407-5FEE-480E-AE59-D12C42D5CBF3Q36441524-99D4751E-A871-4032-B0FD-7EE73F885D9FQ36624970-E7BDE199-198E-463F-9CBB-177B501B9838Q36742397-163D0FBD-8339-46D1-BC24-7F3CF92EA7FEQ36774257-5ED9D1EF-AD57-4F3F-AC6C-0A62622EDBCFQ37213981-1C43CF5B-6314-41CC-A307-1EF8207D55BCQ37345790-8A37899B-DD1B-429A-B281-683AF0CA1EC2Q37827345-BC0B1218-FF3D-4831-9B35-4EACF578B834Q37854724-2E412D71-59E2-46D3-A6A5-C12BF0FF224DQ39458862-A5A27B93-8527-45A9-8283-171F7C77FD0AQ40392475-B164EF07-95DF-45CE-8640-E6EF8368EE2CQ40488737-0F56C05F-84E3-4619-B09C-157D4824F7F4Q40749902-3D31B63B-64D9-4883-B00F-1560540D85CAQ41768914-8CFB7940-28DD-4AE6-98DD-E50F3ED47F0EQ41893115-E28C9272-9D8E-4102-8D01-23C5C5FC8236Q42408710-61946B7E-FA72-44E0-B752-755C49C2ACAEQ42731827-A5D6E065-A2E2-408A-9334-1CA530FD489EQ43479012-5D0CF3BA-0DD4-430F-8941-019B3512EDA0Q48424894-4595B5A4-EAD5-46C0-872B-6298F5611C77Q58839896-56208363-0DAB-474E-BADC-6655E3951FA7
P2860
In vitro activity of anidulafungin against selected clinically important mold isolates
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vitro activity of anidulafungin against selected clinically important mold isolates
@en
In vitro activity of anidulafungin against selected clinically important mold isolates.
@nl
type
label
In vitro activity of anidulafungin against selected clinically important mold isolates
@en
In vitro activity of anidulafungin against selected clinically important mold isolates.
@nl
prefLabel
In vitro activity of anidulafungin against selected clinically important mold isolates
@en
In vitro activity of anidulafungin against selected clinically important mold isolates.
@nl
P2093
P2860
P1476
In vitro activity of anidulafungin against selected clinically important mold isolates
@en
P2093
Jose R Rodriguez
Luis Ostrosky-Zeichner
Victor L Paetznick
Zekaver Odabasi
P2860
P304
P356
10.1128/AAC.48.5.1912-1915.2004
P407
P577
2004-05-01T00:00:00Z